Global Adalimumab (Humira) and Biosimilar Supply, Demand and Key Producers, 2023-2029
The global Adalimumab (Humira) and Biosimilar market size is expected to reach $ 16210 million by 2029, rising at a market growth of -4.9% CAGR during the forecast period (2023-2029).
The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
This report studies the global Adalimumab (Humira) and Biosimilar production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Adalimumab (Humira) and Biosimilar, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Adalimumab (Humira) and Biosimilar that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Adalimumab (Humira) and Biosimilar total production and demand, 2018-2029, (K Units)
Global Adalimumab (Humira) and Biosimilar total production value, 2018-2029, (USD Million)
Global Adalimumab (Humira) and Biosimilar production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Adalimumab (Humira) and Biosimilar consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Adalimumab (Humira) and Biosimilar domestic production, consumption, key domestic manufacturers and share
Global Adalimumab (Humira) and Biosimilar production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Adalimumab (Humira) and Biosimilar production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Adalimumab (Humira) and Biosimilar production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Adalimumab (Humira) and Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen, Boehringer Ingelheim, Novartis, Samsung Bioepis and Viatris, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Adalimumab (Humira) and Biosimilar market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Adalimumab (Humira) and Biosimilar Market, By Region:
1. How big is the global Adalimumab (Humira) and Biosimilar market?
2. What is the demand of the global Adalimumab (Humira) and Biosimilar market?
3. What is the year over year growth of the global Adalimumab (Humira) and Biosimilar market?
4. What is the production and production value of the global Adalimumab (Humira) and Biosimilar market?
5. Who are the key producers in the global Adalimumab (Humira) and Biosimilar market?
6. What are the growth factors driving the market demand?
The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
This report studies the global Adalimumab (Humira) and Biosimilar production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Adalimumab (Humira) and Biosimilar, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Adalimumab (Humira) and Biosimilar that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Adalimumab (Humira) and Biosimilar total production and demand, 2018-2029, (K Units)
Global Adalimumab (Humira) and Biosimilar total production value, 2018-2029, (USD Million)
Global Adalimumab (Humira) and Biosimilar production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Adalimumab (Humira) and Biosimilar consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Adalimumab (Humira) and Biosimilar domestic production, consumption, key domestic manufacturers and share
Global Adalimumab (Humira) and Biosimilar production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Adalimumab (Humira) and Biosimilar production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Adalimumab (Humira) and Biosimilar production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Adalimumab (Humira) and Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen, Boehringer Ingelheim, Novartis, Samsung Bioepis and Viatris, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Adalimumab (Humira) and Biosimilar market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Adalimumab (Humira) and Biosimilar Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Syringe
- Pen
- Ankylosing Spondylitis
- Rheumatoid Arthritis
- Crohn’s Disease
- Other
- AbbVie
- Eisai
- Cadila Healthcare
- Torrent Pharmaceuticals
- Amgen
- Boehringer Ingelheim
- Novartis
- Samsung Bioepis
- Viatris
- Pfizer
- Fresenius Kabi
- Coherus
1. How big is the global Adalimumab (Humira) and Biosimilar market?
2. What is the demand of the global Adalimumab (Humira) and Biosimilar market?
3. What is the year over year growth of the global Adalimumab (Humira) and Biosimilar market?
4. What is the production and production value of the global Adalimumab (Humira) and Biosimilar market?
5. Who are the key producers in the global Adalimumab (Humira) and Biosimilar market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Adalimumab (Humira) and Biosimilar Introduction
1.2 World Adalimumab (Humira) and Biosimilar Supply & Forecast
1.2.1 World Adalimumab (Humira) and Biosimilar Production Value (2018 & 2022 & 2029)
1.2.2 World Adalimumab (Humira) and Biosimilar Production (2018-2029)
1.2.3 World Adalimumab (Humira) and Biosimilar Pricing Trends (2018-2029)
1.3 World Adalimumab (Humira) and Biosimilar Production by Region (Based on Production Site)
1.3.1 World Adalimumab (Humira) and Biosimilar Production Value by Region (2018-2029)
1.3.2 World Adalimumab (Humira) and Biosimilar Production by Region (2018-2029)
1.3.3 World Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2029)
1.3.4 North America Adalimumab (Humira) and Biosimilar Production (2018-2029)
1.3.5 Europe Adalimumab (Humira) and Biosimilar Production (2018-2029)
1.3.6 China Adalimumab (Humira) and Biosimilar Production (2018-2029)
1.3.7 Japan Adalimumab (Humira) and Biosimilar Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Adalimumab (Humira) and Biosimilar Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Adalimumab (Humira) and Biosimilar Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Adalimumab (Humira) and Biosimilar Demand (2018-2029)
2.2 World Adalimumab (Humira) and Biosimilar Consumption by Region
2.2.1 World Adalimumab (Humira) and Biosimilar Consumption by Region (2018-2023)
2.2.2 World Adalimumab (Humira) and Biosimilar Consumption Forecast by Region (2024-2029)
2.3 United States Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
2.4 China Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
2.5 Europe Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
2.6 Japan Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
2.7 South Korea Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
2.8 ASEAN Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
2.9 India Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
3 WORLD ADALIMUMAB (HUMIRA) AND BIOSIMILAR MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Adalimumab (Humira) and Biosimilar Production Value by Manufacturer (2018-2023)
3.2 World Adalimumab (Humira) and Biosimilar Production by Manufacturer (2018-2023)
3.3 World Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Adalimumab (Humira) and Biosimilar Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Adalimumab (Humira) and Biosimilar Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Adalimumab (Humira) and Biosimilar in 2022
3.5.3 Global Concentration Ratios (CR8) for Adalimumab (Humira) and Biosimilar in 2022
3.6 Adalimumab (Humira) and Biosimilar Market: Overall Company Footprint Analysis
3.6.1 Adalimumab (Humira) and Biosimilar Market: Region Footprint
3.6.2 Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint
3.6.3 Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Adalimumab (Humira) and Biosimilar Production Value Comparison
4.1.1 United States VS China: Adalimumab (Humira) and Biosimilar Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Adalimumab (Humira) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Adalimumab (Humira) and Biosimilar Production Comparison
4.2.1 United States VS China: Adalimumab (Humira) and Biosimilar Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Adalimumab (Humira) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Adalimumab (Humira) and Biosimilar Consumption Comparison
4.3.1 United States VS China: Adalimumab (Humira) and Biosimilar Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Adalimumab (Humira) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Adalimumab (Humira) and Biosimilar Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Adalimumab (Humira) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value (2018-2023)
4.4.3 United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production (2018-2023)
4.5 China Based Adalimumab (Humira) and Biosimilar Manufacturers and Market Share
4.5.1 China Based Adalimumab (Humira) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value (2018-2023)
4.5.3 China Based Manufacturers Adalimumab (Humira) and Biosimilar Production (2018-2023)
4.6 Rest of World Based Adalimumab (Humira) and Biosimilar Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Adalimumab (Humira) and Biosimilar Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Adalimumab (Humira) and Biosimilar Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Syringe
5.2.2 Pen
5.3 Market Segment by Type
5.3.1 World Adalimumab (Humira) and Biosimilar Production by Type (2018-2029)
5.3.2 World Adalimumab (Humira) and Biosimilar Production Value by Type (2018-2029)
5.3.3 World Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Adalimumab (Humira) and Biosimilar Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Ankylosing Spondylitis
6.2.2 Rheumatoid Arthritis
6.2.3 Crohn’s Disease
6.2.4 Other
6.3 Market Segment by Application
6.3.1 World Adalimumab (Humira) and Biosimilar Production by Application (2018-2029)
6.3.2 World Adalimumab (Humira) and Biosimilar Production Value by Application (2018-2029)
6.3.3 World Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 AbbVie
7.1.1 AbbVie Details
7.1.2 AbbVie Major Business
7.1.3 AbbVie Adalimumab (Humira) and Biosimilar Product and Services
7.1.4 AbbVie Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 AbbVie Recent Developments/Updates
7.1.6 AbbVie Competitive Strengths & Weaknesses
7.2 Eisai
7.2.1 Eisai Details
7.2.2 Eisai Major Business
7.2.3 Eisai Adalimumab (Humira) and Biosimilar Product and Services
7.2.4 Eisai Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Eisai Recent Developments/Updates
7.2.6 Eisai Competitive Strengths & Weaknesses
7.3 Cadila Healthcare
7.3.1 Cadila Healthcare Details
7.3.2 Cadila Healthcare Major Business
7.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services
7.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Cadila Healthcare Recent Developments/Updates
7.3.6 Cadila Healthcare Competitive Strengths & Weaknesses
7.4 Torrent Pharmaceuticals
7.4.1 Torrent Pharmaceuticals Details
7.4.2 Torrent Pharmaceuticals Major Business
7.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services
7.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Torrent Pharmaceuticals Recent Developments/Updates
7.4.6 Torrent Pharmaceuticals Competitive Strengths & Weaknesses
7.5 Amgen
7.5.1 Amgen Details
7.5.2 Amgen Major Business
7.5.3 Amgen Adalimumab (Humira) and Biosimilar Product and Services
7.5.4 Amgen Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Amgen Recent Developments/Updates
7.5.6 Amgen Competitive Strengths & Weaknesses
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Details
7.6.2 Boehringer Ingelheim Major Business
7.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services
7.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Boehringer Ingelheim Recent Developments/Updates
7.6.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
7.7 Novartis
7.7.1 Novartis Details
7.7.2 Novartis Major Business
7.7.3 Novartis Adalimumab (Humira) and Biosimilar Product and Services
7.7.4 Novartis Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Novartis Recent Developments/Updates
7.7.6 Novartis Competitive Strengths & Weaknesses
7.8 Samsung Bioepis
7.8.1 Samsung Bioepis Details
7.8.2 Samsung Bioepis Major Business
7.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services
7.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Samsung Bioepis Recent Developments/Updates
7.8.6 Samsung Bioepis Competitive Strengths & Weaknesses
7.9 Viatris
7.9.1 Viatris Details
7.9.2 Viatris Major Business
7.9.3 Viatris Adalimumab (Humira) and Biosimilar Product and Services
7.9.4 Viatris Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Viatris Recent Developments/Updates
7.9.6 Viatris Competitive Strengths & Weaknesses
7.10 Pfizer
7.10.1 Pfizer Details
7.10.2 Pfizer Major Business
7.10.3 Pfizer Adalimumab (Humira) and Biosimilar Product and Services
7.10.4 Pfizer Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Pfizer Recent Developments/Updates
7.10.6 Pfizer Competitive Strengths & Weaknesses
7.11 Fresenius Kabi
7.11.1 Fresenius Kabi Details
7.11.2 Fresenius Kabi Major Business
7.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services
7.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Fresenius Kabi Recent Developments/Updates
7.11.6 Fresenius Kabi Competitive Strengths & Weaknesses
7.12 Coherus
7.12.1 Coherus Details
7.12.2 Coherus Major Business
7.12.3 Coherus Adalimumab (Humira) and Biosimilar Product and Services
7.12.4 Coherus Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Coherus Recent Developments/Updates
7.12.6 Coherus Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Adalimumab (Humira) and Biosimilar Industry Chain
8.2 Adalimumab (Humira) and Biosimilar Upstream Analysis
8.2.1 Adalimumab (Humira) and Biosimilar Core Raw Materials
8.2.2 Main Manufacturers of Adalimumab (Humira) and Biosimilar Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Adalimumab (Humira) and Biosimilar Production Mode
8.6 Adalimumab (Humira) and Biosimilar Procurement Model
8.7 Adalimumab (Humira) and Biosimilar Industry Sales Model and Sales Channels
8.7.1 Adalimumab (Humira) and Biosimilar Sales Model
8.7.2 Adalimumab (Humira) and Biosimilar Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Adalimumab (Humira) and Biosimilar Introduction
1.2 World Adalimumab (Humira) and Biosimilar Supply & Forecast
1.2.1 World Adalimumab (Humira) and Biosimilar Production Value (2018 & 2022 & 2029)
1.2.2 World Adalimumab (Humira) and Biosimilar Production (2018-2029)
1.2.3 World Adalimumab (Humira) and Biosimilar Pricing Trends (2018-2029)
1.3 World Adalimumab (Humira) and Biosimilar Production by Region (Based on Production Site)
1.3.1 World Adalimumab (Humira) and Biosimilar Production Value by Region (2018-2029)
1.3.2 World Adalimumab (Humira) and Biosimilar Production by Region (2018-2029)
1.3.3 World Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2029)
1.3.4 North America Adalimumab (Humira) and Biosimilar Production (2018-2029)
1.3.5 Europe Adalimumab (Humira) and Biosimilar Production (2018-2029)
1.3.6 China Adalimumab (Humira) and Biosimilar Production (2018-2029)
1.3.7 Japan Adalimumab (Humira) and Biosimilar Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Adalimumab (Humira) and Biosimilar Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Adalimumab (Humira) and Biosimilar Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Adalimumab (Humira) and Biosimilar Demand (2018-2029)
2.2 World Adalimumab (Humira) and Biosimilar Consumption by Region
2.2.1 World Adalimumab (Humira) and Biosimilar Consumption by Region (2018-2023)
2.2.2 World Adalimumab (Humira) and Biosimilar Consumption Forecast by Region (2024-2029)
2.3 United States Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
2.4 China Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
2.5 Europe Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
2.6 Japan Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
2.7 South Korea Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
2.8 ASEAN Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
2.9 India Adalimumab (Humira) and Biosimilar Consumption (2018-2029)
3 WORLD ADALIMUMAB (HUMIRA) AND BIOSIMILAR MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Adalimumab (Humira) and Biosimilar Production Value by Manufacturer (2018-2023)
3.2 World Adalimumab (Humira) and Biosimilar Production by Manufacturer (2018-2023)
3.3 World Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Adalimumab (Humira) and Biosimilar Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Adalimumab (Humira) and Biosimilar Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Adalimumab (Humira) and Biosimilar in 2022
3.5.3 Global Concentration Ratios (CR8) for Adalimumab (Humira) and Biosimilar in 2022
3.6 Adalimumab (Humira) and Biosimilar Market: Overall Company Footprint Analysis
3.6.1 Adalimumab (Humira) and Biosimilar Market: Region Footprint
3.6.2 Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint
3.6.3 Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Adalimumab (Humira) and Biosimilar Production Value Comparison
4.1.1 United States VS China: Adalimumab (Humira) and Biosimilar Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Adalimumab (Humira) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Adalimumab (Humira) and Biosimilar Production Comparison
4.2.1 United States VS China: Adalimumab (Humira) and Biosimilar Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Adalimumab (Humira) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Adalimumab (Humira) and Biosimilar Consumption Comparison
4.3.1 United States VS China: Adalimumab (Humira) and Biosimilar Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Adalimumab (Humira) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Adalimumab (Humira) and Biosimilar Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Adalimumab (Humira) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value (2018-2023)
4.4.3 United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production (2018-2023)
4.5 China Based Adalimumab (Humira) and Biosimilar Manufacturers and Market Share
4.5.1 China Based Adalimumab (Humira) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value (2018-2023)
4.5.3 China Based Manufacturers Adalimumab (Humira) and Biosimilar Production (2018-2023)
4.6 Rest of World Based Adalimumab (Humira) and Biosimilar Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Adalimumab (Humira) and Biosimilar Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Adalimumab (Humira) and Biosimilar Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Syringe
5.2.2 Pen
5.3 Market Segment by Type
5.3.1 World Adalimumab (Humira) and Biosimilar Production by Type (2018-2029)
5.3.2 World Adalimumab (Humira) and Biosimilar Production Value by Type (2018-2029)
5.3.3 World Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Adalimumab (Humira) and Biosimilar Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Ankylosing Spondylitis
6.2.2 Rheumatoid Arthritis
6.2.3 Crohn’s Disease
6.2.4 Other
6.3 Market Segment by Application
6.3.1 World Adalimumab (Humira) and Biosimilar Production by Application (2018-2029)
6.3.2 World Adalimumab (Humira) and Biosimilar Production Value by Application (2018-2029)
6.3.3 World Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 AbbVie
7.1.1 AbbVie Details
7.1.2 AbbVie Major Business
7.1.3 AbbVie Adalimumab (Humira) and Biosimilar Product and Services
7.1.4 AbbVie Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 AbbVie Recent Developments/Updates
7.1.6 AbbVie Competitive Strengths & Weaknesses
7.2 Eisai
7.2.1 Eisai Details
7.2.2 Eisai Major Business
7.2.3 Eisai Adalimumab (Humira) and Biosimilar Product and Services
7.2.4 Eisai Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Eisai Recent Developments/Updates
7.2.6 Eisai Competitive Strengths & Weaknesses
7.3 Cadila Healthcare
7.3.1 Cadila Healthcare Details
7.3.2 Cadila Healthcare Major Business
7.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services
7.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Cadila Healthcare Recent Developments/Updates
7.3.6 Cadila Healthcare Competitive Strengths & Weaknesses
7.4 Torrent Pharmaceuticals
7.4.1 Torrent Pharmaceuticals Details
7.4.2 Torrent Pharmaceuticals Major Business
7.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services
7.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Torrent Pharmaceuticals Recent Developments/Updates
7.4.6 Torrent Pharmaceuticals Competitive Strengths & Weaknesses
7.5 Amgen
7.5.1 Amgen Details
7.5.2 Amgen Major Business
7.5.3 Amgen Adalimumab (Humira) and Biosimilar Product and Services
7.5.4 Amgen Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Amgen Recent Developments/Updates
7.5.6 Amgen Competitive Strengths & Weaknesses
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Details
7.6.2 Boehringer Ingelheim Major Business
7.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services
7.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Boehringer Ingelheim Recent Developments/Updates
7.6.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
7.7 Novartis
7.7.1 Novartis Details
7.7.2 Novartis Major Business
7.7.3 Novartis Adalimumab (Humira) and Biosimilar Product and Services
7.7.4 Novartis Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Novartis Recent Developments/Updates
7.7.6 Novartis Competitive Strengths & Weaknesses
7.8 Samsung Bioepis
7.8.1 Samsung Bioepis Details
7.8.2 Samsung Bioepis Major Business
7.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services
7.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Samsung Bioepis Recent Developments/Updates
7.8.6 Samsung Bioepis Competitive Strengths & Weaknesses
7.9 Viatris
7.9.1 Viatris Details
7.9.2 Viatris Major Business
7.9.3 Viatris Adalimumab (Humira) and Biosimilar Product and Services
7.9.4 Viatris Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Viatris Recent Developments/Updates
7.9.6 Viatris Competitive Strengths & Weaknesses
7.10 Pfizer
7.10.1 Pfizer Details
7.10.2 Pfizer Major Business
7.10.3 Pfizer Adalimumab (Humira) and Biosimilar Product and Services
7.10.4 Pfizer Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Pfizer Recent Developments/Updates
7.10.6 Pfizer Competitive Strengths & Weaknesses
7.11 Fresenius Kabi
7.11.1 Fresenius Kabi Details
7.11.2 Fresenius Kabi Major Business
7.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services
7.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Fresenius Kabi Recent Developments/Updates
7.11.6 Fresenius Kabi Competitive Strengths & Weaknesses
7.12 Coherus
7.12.1 Coherus Details
7.12.2 Coherus Major Business
7.12.3 Coherus Adalimumab (Humira) and Biosimilar Product and Services
7.12.4 Coherus Adalimumab (Humira) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Coherus Recent Developments/Updates
7.12.6 Coherus Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Adalimumab (Humira) and Biosimilar Industry Chain
8.2 Adalimumab (Humira) and Biosimilar Upstream Analysis
8.2.1 Adalimumab (Humira) and Biosimilar Core Raw Materials
8.2.2 Main Manufacturers of Adalimumab (Humira) and Biosimilar Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Adalimumab (Humira) and Biosimilar Production Mode
8.6 Adalimumab (Humira) and Biosimilar Procurement Model
8.7 Adalimumab (Humira) and Biosimilar Industry Sales Model and Sales Channels
8.7.1 Adalimumab (Humira) and Biosimilar Sales Model
8.7.2 Adalimumab (Humira) and Biosimilar Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Adalimumab (Humira) and Biosimilar Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Adalimumab (Humira) and Biosimilar Production Value by Region (2018-2023) & (USD Million)
Table 3. World Adalimumab (Humira) and Biosimilar Production Value by Region (2024-2029) & (USD Million)
Table 4. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Region (2018-2023)
Table 5. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Region (2024-2029)
Table 6. World Adalimumab (Humira) and Biosimilar Production by Region (2018-2023) & (K Units)
Table 7. World Adalimumab (Humira) and Biosimilar Production by Region (2024-2029) & (K Units)
Table 8. World Adalimumab (Humira) and Biosimilar Production Market Share by Region (2018-2023)
Table 9. World Adalimumab (Humira) and Biosimilar Production Market Share by Region (2024-2029)
Table 10. World Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Adalimumab (Humira) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Adalimumab (Humira) and Biosimilar Major Market Trends
Table 13. World Adalimumab (Humira) and Biosimilar Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Adalimumab (Humira) and Biosimilar Consumption by Region (2018-2023) & (K Units)
Table 15. World Adalimumab (Humira) and Biosimilar Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Adalimumab (Humira) and Biosimilar Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Adalimumab (Humira) and Biosimilar Producers in 2022
Table 18. World Adalimumab (Humira) and Biosimilar Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Adalimumab (Humira) and Biosimilar Producers in 2022
Table 20. World Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Adalimumab (Humira) and Biosimilar Company Evaluation Quadrant
Table 22. World Adalimumab (Humira) and Biosimilar Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Adalimumab (Humira) and Biosimilar Production Site of Key Manufacturer
Table 24. Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint
Table 25. Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint
Table 26. Adalimumab (Humira) and Biosimilar Competitive Factors
Table 27. Adalimumab (Humira) and Biosimilar New Entrant and Capacity Expansion Plans
Table 28. Adalimumab (Humira) and Biosimilar Mergers & Acquisitions Activity
Table 29. United States VS China Adalimumab (Humira) and Biosimilar Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Adalimumab (Humira) and Biosimilar Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Adalimumab (Humira) and Biosimilar Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Adalimumab (Humira) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production Market Share (2018-2023)
Table 37. China Based Adalimumab (Humira) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Adalimumab (Humira) and Biosimilar Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Adalimumab (Humira) and Biosimilar Production Market Share (2018-2023)
Table 42. Rest of World Based Adalimumab (Humira) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production Market Share (2018-2023)
Table 47. World Adalimumab (Humira) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Adalimumab (Humira) and Biosimilar Production by Type (2018-2023) & (K Units)
Table 49. World Adalimumab (Humira) and Biosimilar Production by Type (2024-2029) & (K Units)
Table 50. World Adalimumab (Humira) and Biosimilar Production Value by Type (2018-2023) & (USD Million)
Table 51. World Adalimumab (Humira) and Biosimilar Production Value by Type (2024-2029) & (USD Million)
Table 52. World Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Adalimumab (Humira) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Adalimumab (Humira) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Adalimumab (Humira) and Biosimilar Production by Application (2018-2023) & (K Units)
Table 56. World Adalimumab (Humira) and Biosimilar Production by Application (2024-2029) & (K Units)
Table 57. World Adalimumab (Humira) and Biosimilar Production Value by Application (2018-2023) & (USD Million)
Table 58. World Adalimumab (Humira) and Biosimilar Production Value by Application (2024-2029) & (USD Million)
Table 59. World Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Adalimumab (Humira) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 61. AbbVie Basic Information, Manufacturing Base and Competitors
Table 62. AbbVie Major Business
Table 63. AbbVie Adalimumab (Humira) and Biosimilar Product and Services
Table 64. AbbVie Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. AbbVie Recent Developments/Updates
Table 66. AbbVie Competitive Strengths & Weaknesses
Table 67. Eisai Basic Information, Manufacturing Base and Competitors
Table 68. Eisai Major Business
Table 69. Eisai Adalimumab (Humira) and Biosimilar Product and Services
Table 70. Eisai Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Eisai Recent Developments/Updates
Table 72. Eisai Competitive Strengths & Weaknesses
Table 73. Cadila Healthcare Basic Information, Manufacturing Base and Competitors
Table 74. Cadila Healthcare Major Business
Table 75. Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services
Table 76. Cadila Healthcare Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Cadila Healthcare Recent Developments/Updates
Table 78. Cadila Healthcare Competitive Strengths & Weaknesses
Table 79. Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 80. Torrent Pharmaceuticals Major Business
Table 81. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services
Table 82. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Torrent Pharmaceuticals Recent Developments/Updates
Table 84. Torrent Pharmaceuticals Competitive Strengths & Weaknesses
Table 85. Amgen Basic Information, Manufacturing Base and Competitors
Table 86. Amgen Major Business
Table 87. Amgen Adalimumab (Humira) and Biosimilar Product and Services
Table 88. Amgen Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Amgen Recent Developments/Updates
Table 90. Amgen Competitive Strengths & Weaknesses
Table 91. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 92. Boehringer Ingelheim Major Business
Table 93. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services
Table 94. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Boehringer Ingelheim Recent Developments/Updates
Table 96. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 97. Novartis Basic Information, Manufacturing Base and Competitors
Table 98. Novartis Major Business
Table 99. Novartis Adalimumab (Humira) and Biosimilar Product and Services
Table 100. Novartis Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Novartis Recent Developments/Updates
Table 102. Novartis Competitive Strengths & Weaknesses
Table 103. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 104. Samsung Bioepis Major Business
Table 105. Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services
Table 106. Samsung Bioepis Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Samsung Bioepis Recent Developments/Updates
Table 108. Samsung Bioepis Competitive Strengths & Weaknesses
Table 109. Viatris Basic Information, Manufacturing Base and Competitors
Table 110. Viatris Major Business
Table 111. Viatris Adalimumab (Humira) and Biosimilar Product and Services
Table 112. Viatris Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. Viatris Recent Developments/Updates
Table 114. Viatris Competitive Strengths & Weaknesses
Table 115. Pfizer Basic Information, Manufacturing Base and Competitors
Table 116. Pfizer Major Business
Table 117. Pfizer Adalimumab (Humira) and Biosimilar Product and Services
Table 118. Pfizer Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Pfizer Recent Developments/Updates
Table 120. Pfizer Competitive Strengths & Weaknesses
Table 121. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 122. Fresenius Kabi Major Business
Table 123. Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services
Table 124. Fresenius Kabi Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Fresenius Kabi Recent Developments/Updates
Table 126. Coherus Basic Information, Manufacturing Base and Competitors
Table 127. Coherus Major Business
Table 128. Coherus Adalimumab (Humira) and Biosimilar Product and Services
Table 129. Coherus Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 130. Global Key Players of Adalimumab (Humira) and Biosimilar Upstream (Raw Materials)
Table 131. Adalimumab (Humira) and Biosimilar Typical Customers
Table 132. Adalimumab (Humira) and Biosimilar Typical Distributors
Table 1. World Adalimumab (Humira) and Biosimilar Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Adalimumab (Humira) and Biosimilar Production Value by Region (2018-2023) & (USD Million)
Table 3. World Adalimumab (Humira) and Biosimilar Production Value by Region (2024-2029) & (USD Million)
Table 4. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Region (2018-2023)
Table 5. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Region (2024-2029)
Table 6. World Adalimumab (Humira) and Biosimilar Production by Region (2018-2023) & (K Units)
Table 7. World Adalimumab (Humira) and Biosimilar Production by Region (2024-2029) & (K Units)
Table 8. World Adalimumab (Humira) and Biosimilar Production Market Share by Region (2018-2023)
Table 9. World Adalimumab (Humira) and Biosimilar Production Market Share by Region (2024-2029)
Table 10. World Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Adalimumab (Humira) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Adalimumab (Humira) and Biosimilar Major Market Trends
Table 13. World Adalimumab (Humira) and Biosimilar Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Adalimumab (Humira) and Biosimilar Consumption by Region (2018-2023) & (K Units)
Table 15. World Adalimumab (Humira) and Biosimilar Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Adalimumab (Humira) and Biosimilar Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Adalimumab (Humira) and Biosimilar Producers in 2022
Table 18. World Adalimumab (Humira) and Biosimilar Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Adalimumab (Humira) and Biosimilar Producers in 2022
Table 20. World Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Adalimumab (Humira) and Biosimilar Company Evaluation Quadrant
Table 22. World Adalimumab (Humira) and Biosimilar Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Adalimumab (Humira) and Biosimilar Production Site of Key Manufacturer
Table 24. Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint
Table 25. Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint
Table 26. Adalimumab (Humira) and Biosimilar Competitive Factors
Table 27. Adalimumab (Humira) and Biosimilar New Entrant and Capacity Expansion Plans
Table 28. Adalimumab (Humira) and Biosimilar Mergers & Acquisitions Activity
Table 29. United States VS China Adalimumab (Humira) and Biosimilar Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Adalimumab (Humira) and Biosimilar Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Adalimumab (Humira) and Biosimilar Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Adalimumab (Humira) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production Market Share (2018-2023)
Table 37. China Based Adalimumab (Humira) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Adalimumab (Humira) and Biosimilar Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Adalimumab (Humira) and Biosimilar Production Market Share (2018-2023)
Table 42. Rest of World Based Adalimumab (Humira) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production Market Share (2018-2023)
Table 47. World Adalimumab (Humira) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Adalimumab (Humira) and Biosimilar Production by Type (2018-2023) & (K Units)
Table 49. World Adalimumab (Humira) and Biosimilar Production by Type (2024-2029) & (K Units)
Table 50. World Adalimumab (Humira) and Biosimilar Production Value by Type (2018-2023) & (USD Million)
Table 51. World Adalimumab (Humira) and Biosimilar Production Value by Type (2024-2029) & (USD Million)
Table 52. World Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Adalimumab (Humira) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Adalimumab (Humira) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Adalimumab (Humira) and Biosimilar Production by Application (2018-2023) & (K Units)
Table 56. World Adalimumab (Humira) and Biosimilar Production by Application (2024-2029) & (K Units)
Table 57. World Adalimumab (Humira) and Biosimilar Production Value by Application (2018-2023) & (USD Million)
Table 58. World Adalimumab (Humira) and Biosimilar Production Value by Application (2024-2029) & (USD Million)
Table 59. World Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Adalimumab (Humira) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 61. AbbVie Basic Information, Manufacturing Base and Competitors
Table 62. AbbVie Major Business
Table 63. AbbVie Adalimumab (Humira) and Biosimilar Product and Services
Table 64. AbbVie Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. AbbVie Recent Developments/Updates
Table 66. AbbVie Competitive Strengths & Weaknesses
Table 67. Eisai Basic Information, Manufacturing Base and Competitors
Table 68. Eisai Major Business
Table 69. Eisai Adalimumab (Humira) and Biosimilar Product and Services
Table 70. Eisai Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Eisai Recent Developments/Updates
Table 72. Eisai Competitive Strengths & Weaknesses
Table 73. Cadila Healthcare Basic Information, Manufacturing Base and Competitors
Table 74. Cadila Healthcare Major Business
Table 75. Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services
Table 76. Cadila Healthcare Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Cadila Healthcare Recent Developments/Updates
Table 78. Cadila Healthcare Competitive Strengths & Weaknesses
Table 79. Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 80. Torrent Pharmaceuticals Major Business
Table 81. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services
Table 82. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Torrent Pharmaceuticals Recent Developments/Updates
Table 84. Torrent Pharmaceuticals Competitive Strengths & Weaknesses
Table 85. Amgen Basic Information, Manufacturing Base and Competitors
Table 86. Amgen Major Business
Table 87. Amgen Adalimumab (Humira) and Biosimilar Product and Services
Table 88. Amgen Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Amgen Recent Developments/Updates
Table 90. Amgen Competitive Strengths & Weaknesses
Table 91. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 92. Boehringer Ingelheim Major Business
Table 93. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services
Table 94. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Boehringer Ingelheim Recent Developments/Updates
Table 96. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 97. Novartis Basic Information, Manufacturing Base and Competitors
Table 98. Novartis Major Business
Table 99. Novartis Adalimumab (Humira) and Biosimilar Product and Services
Table 100. Novartis Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Novartis Recent Developments/Updates
Table 102. Novartis Competitive Strengths & Weaknesses
Table 103. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 104. Samsung Bioepis Major Business
Table 105. Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services
Table 106. Samsung Bioepis Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Samsung Bioepis Recent Developments/Updates
Table 108. Samsung Bioepis Competitive Strengths & Weaknesses
Table 109. Viatris Basic Information, Manufacturing Base and Competitors
Table 110. Viatris Major Business
Table 111. Viatris Adalimumab (Humira) and Biosimilar Product and Services
Table 112. Viatris Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. Viatris Recent Developments/Updates
Table 114. Viatris Competitive Strengths & Weaknesses
Table 115. Pfizer Basic Information, Manufacturing Base and Competitors
Table 116. Pfizer Major Business
Table 117. Pfizer Adalimumab (Humira) and Biosimilar Product and Services
Table 118. Pfizer Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Pfizer Recent Developments/Updates
Table 120. Pfizer Competitive Strengths & Weaknesses
Table 121. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 122. Fresenius Kabi Major Business
Table 123. Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services
Table 124. Fresenius Kabi Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Fresenius Kabi Recent Developments/Updates
Table 126. Coherus Basic Information, Manufacturing Base and Competitors
Table 127. Coherus Major Business
Table 128. Coherus Adalimumab (Humira) and Biosimilar Product and Services
Table 129. Coherus Adalimumab (Humira) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 130. Global Key Players of Adalimumab (Humira) and Biosimilar Upstream (Raw Materials)
Table 131. Adalimumab (Humira) and Biosimilar Typical Customers
Table 132. Adalimumab (Humira) and Biosimilar Typical Distributors
LIST OF FIGURES
Figure 1. Adalimumab (Humira) and Biosimilar Picture
Figure 2. World Adalimumab (Humira) and Biosimilar Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Adalimumab (Humira) and Biosimilar Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Adalimumab (Humira) and Biosimilar Production (2018-2029) & (K Units)
Figure 5. World Adalimumab (Humira) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 6. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Region (2018-2029)
Figure 7. World Adalimumab (Humira) and Biosimilar Production Market Share by Region (2018-2029)
Figure 8. North America Adalimumab (Humira) and Biosimilar Production (2018-2029) & (K Units)
Figure 9. Europe Adalimumab (Humira) and Biosimilar Production (2018-2029) & (K Units)
Figure 10. China Adalimumab (Humira) and Biosimilar Production (2018-2029) & (K Units)
Figure 11. Japan Adalimumab (Humira) and Biosimilar Production (2018-2029) & (K Units)
Figure 12. Adalimumab (Humira) and Biosimilar Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 15. World Adalimumab (Humira) and Biosimilar Consumption Market Share by Region (2018-2029)
Figure 16. United States Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 17. China Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 18. Europe Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 19. Japan Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 20. South Korea Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 22. India Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Adalimumab (Humira) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Adalimumab (Humira) and Biosimilar Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Adalimumab (Humira) and Biosimilar Markets in 2022
Figure 26. United States VS China: Adalimumab (Humira) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Adalimumab (Humira) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Adalimumab (Humira) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production Market Share 2022
Figure 30. China Based Manufacturers Adalimumab (Humira) and Biosimilar Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production Market Share 2022
Figure 32. World Adalimumab (Humira) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Type in 2022
Figure 34. Syringe
Figure 35. Pen
Figure 36. World Adalimumab (Humira) and Biosimilar Production Market Share by Type (2018-2029)
Figure 37. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Type (2018-2029)
Figure 38. World Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 39. World Adalimumab (Humira) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 40. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Application in 2022
Figure 41. Ankylosing Spondylitis
Figure 42. Rheumatoid Arthritis
Figure 43. Crohn’s Disease
Figure 44. Other
Figure 45. World Adalimumab (Humira) and Biosimilar Production Market Share by Application (2018-2029)
Figure 46. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Application (2018-2029)
Figure 47. World Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 48. Adalimumab (Humira) and Biosimilar Industry Chain
Figure 49. Adalimumab (Humira) and Biosimilar Procurement Model
Figure 50. Adalimumab (Humira) and Biosimilar Sales Model
Figure 51. Adalimumab (Humira) and Biosimilar Sales Channels, Direct Sales, and Distribution
Figure 52. Methodology
Figure 53. Research Process and Data Source
Figure 1. Adalimumab (Humira) and Biosimilar Picture
Figure 2. World Adalimumab (Humira) and Biosimilar Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Adalimumab (Humira) and Biosimilar Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Adalimumab (Humira) and Biosimilar Production (2018-2029) & (K Units)
Figure 5. World Adalimumab (Humira) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 6. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Region (2018-2029)
Figure 7. World Adalimumab (Humira) and Biosimilar Production Market Share by Region (2018-2029)
Figure 8. North America Adalimumab (Humira) and Biosimilar Production (2018-2029) & (K Units)
Figure 9. Europe Adalimumab (Humira) and Biosimilar Production (2018-2029) & (K Units)
Figure 10. China Adalimumab (Humira) and Biosimilar Production (2018-2029) & (K Units)
Figure 11. Japan Adalimumab (Humira) and Biosimilar Production (2018-2029) & (K Units)
Figure 12. Adalimumab (Humira) and Biosimilar Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 15. World Adalimumab (Humira) and Biosimilar Consumption Market Share by Region (2018-2029)
Figure 16. United States Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 17. China Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 18. Europe Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 19. Japan Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 20. South Korea Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 22. India Adalimumab (Humira) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Adalimumab (Humira) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Adalimumab (Humira) and Biosimilar Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Adalimumab (Humira) and Biosimilar Markets in 2022
Figure 26. United States VS China: Adalimumab (Humira) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Adalimumab (Humira) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Adalimumab (Humira) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Adalimumab (Humira) and Biosimilar Production Market Share 2022
Figure 30. China Based Manufacturers Adalimumab (Humira) and Biosimilar Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Adalimumab (Humira) and Biosimilar Production Market Share 2022
Figure 32. World Adalimumab (Humira) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Type in 2022
Figure 34. Syringe
Figure 35. Pen
Figure 36. World Adalimumab (Humira) and Biosimilar Production Market Share by Type (2018-2029)
Figure 37. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Type (2018-2029)
Figure 38. World Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 39. World Adalimumab (Humira) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 40. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Application in 2022
Figure 41. Ankylosing Spondylitis
Figure 42. Rheumatoid Arthritis
Figure 43. Crohn’s Disease
Figure 44. Other
Figure 45. World Adalimumab (Humira) and Biosimilar Production Market Share by Application (2018-2029)
Figure 46. World Adalimumab (Humira) and Biosimilar Production Value Market Share by Application (2018-2029)
Figure 47. World Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 48. Adalimumab (Humira) and Biosimilar Industry Chain
Figure 49. Adalimumab (Humira) and Biosimilar Procurement Model
Figure 50. Adalimumab (Humira) and Biosimilar Sales Model
Figure 51. Adalimumab (Humira) and Biosimilar Sales Channels, Direct Sales, and Distribution
Figure 52. Methodology
Figure 53. Research Process and Data Source
